ArticleBMC gastroenterology2026
Alkaline sphingomyelinase (ENPP7) attenuates DSS-induced colitis by modulating FOXO1-mediated antioxidative stress responses.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlkaline sphingomyelinase (alk-SMase), also known as ectonucleotide pyrophosphatase/phosphodiesterase 7 (ENPP7), is an intestinal enzyme involved in sphingolipid metabolism and has been implicated in the regulation of inflammation. However, its role in intestinal inflammation and the underlying mechanisms remain unclear. This study aimed to investigate the role of ENPP7 in dextran sulfate sodium (DSS)-induced colitis, with a particular focus on oxidative stress and FOXO1-related signaling pathways.
methodsENPP7 knockout (KO) and wild-type (WT) mice were used to establish a DSS-induced colitis model. Disease severity was assessed by body weight change, disease activity index (DAI), colon length, histopathological analysis, and plasma oxidative stress markers. Levels of pro-inflammatory cytokines and antioxidant enzymes were measured using standard biochemical assays. In vitro, polarized Caco-2 cells were subjected to ENPP7 knockdown and FOXO1 overexpression to evaluate their roles in antioxidative responses.
resultsENPP7 deficiency significantly aggravated DSS-induced colitis, as evidenced by greater body weight loss, higher DAI scores, and shorter colon length. This effect was accompanied by reduced FOXO1 expression, and was associated with diminished antioxidant defense and mitochondrial dysfunction-related alterations. Additionally, KO mice showed increased levels of pro-inflammatory cytokines (IL-1β and TNF-α) and decreased activities of antioxidant enzymes (CAT and SOD1) in intestinal mucosal tissues compared with WT mice. In Caco-2 cells, ENPP7 knockdown reduced FOXO1 expression, which was associated with impaired antioxidant capacity, whereas FOXO1 overexpression partially reversed these effects.
conclusionsENPP7 attenuates DSS-induced colitis, at least in part, by modulating FOXO1-mediated antioxidant responses, thereby influencing oxidative stress and inflammatory processes. These findings highlight ENPP7 as a potential therapeutic target for ulcerative colitis, although further mechanistic and clinical studies are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.